

## PHARMACEUTICAL SCIENCE IN THE ERA OF ARTIFICIAL INTELLIGENCE

**Dhairya Gambhir\*, Kanishek Tiwari, Govind Saini, Himanshu Dhakad, Keshav Yadav**

Mahatma Gandhi College Of Pharmaceutical Sciences Jaipur.

*Article Received: 7 January 2026 | Article Revised: 28 January 2026 | Article Accepted: 17 February 2026*

**\*Corresponding Author: Dhairya Gambhir**

Mahatma Gandhi College Of Pharmaceutical Sciences Jaipur.

**How to cite this Article:** Dhairya Gambhir, Kanishek Tiwari, Govind Saini, Himanshu Dhakad, Keshav Yadav (2026) PHARMACEUTICAL SCIENCE IN THE ERA OF ARTIFICIAL INTELLIGENCE. World Journal of Pharmaceutical Science and Research, 5(3), 105-122.



Copyright © 2026 Dhairya Gambhir | World Journal of Pharmaceutical Science and Research.

This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

### ABSTRACT

**Purpose:** This review discovers the transformative impression of Artificial Intelligence (AI) and Machine Learning (ML) on the pharmaceutical industry and healthcare delivery, focusing on drug discovery, clinical pharmacy practice, and operational productivity. **Methods:** The article inspects the historical development of AI, from early neural models to modern deep learning designs like GANs, RNNs, and Transformers, and assesses their specific requests transversely to the drug life span. **Results:** AI is publicised to significantly accelerate R&D by detecting drug leads quicker and adjusting clinical trials through patient-specific data analysis. In clinical settings, AI-driven choice support systems boost patient safety by reducing medication errors, predicting adverse reactions, and refining adherence—especially realising a 40% growth in adherence in community pharmacies. Still, technologies such as computer vision are restyling medicine supervision and analytical precision in medical imagination. **Challenges:** In spite of these benefits, the evolution characteristics sprints with "black box" interpretability, data privacy risks, algorithmic bias, and high implementation charges. **Conclusion:** This review highlights that despite the fact AI is redesigning pharmacy into an extra detailed and inventive field, its innocuous integration requires a specialised workforce exercise, strong governing agendas, and a constant emphasis on the vital social assembly in patient care.

**KEYWORDS:** Artificial Intelligence, Technology, Pharmaceuticals, Drug Formulation, Challenges.

## 1. INTRODUCTION

Artificial Intelligence (AI) is a stream which immensely contributes its productivity to science related to intelligent machine learning (ML), mainly intellectual computer programs, which provide results in a comparable way to the human attention process. This process generally covers obtaining data, raising resourceful systems for the uses of obtained data, demonstrating definite or estimated conclusions and self-corrections/modifications. In general, AI is used for analysing machine learning (ML) to replicate the reasoning tasks of individuals. AI technology is trained to perform more precise studies as well as to achieve useful explanations.<sup>[1]</sup>

Recently, AI technology has become a very essential part of industry for the beneficial applications in many methodological and research fields. The growing resourcefulness of accepting the applications of AI technology in pharmacy, as well as drug discovery, drug designing, drug diagnosis and drug delivery formulation advances, and other healthcare applications, has by now been lifted from buildup towards expectation.<sup>[2]</sup>

Drug development is a procedure that is very exclusive, time-consuming, and subject to several guidelines in the pharmaceutical industry. A vital modification in the accomplishment rate of drug progress has been the overview of artificial intelligence (AI), deep learning (DL), machine learning (ML), and computational chemistry.<sup>[3]</sup>

In recent times, there has been an incredible rise in the number of pharmaceutical firms and startups engaging AI in drug research and development. Numerous pharmaceutical firms, like Novartis and Pfizer with IBM Watson, have either united with or bought AI technologies.<sup>[4]</sup>

The uses of AI models also make it possible to predict the in vivo responses, pharmacokinetic limitations of the therapeutics, suitable dosing, etc. According to the importance of pharmacokinetic estimates of drugs, the uses of models simplify their effectiveness and inexpensiveness in drug research. There are two significant programmes of AI technology growth. The first one includes the predictable computing procedures, including expert systems, which are capable of putting on the human experiences and explaining the conclusion from the principles, like expert systems. The second one covers the systems, which can model the mode of brain functioning using the artificial neural networks (ANNs). Specifically, various ANNs, like deep neural networks (DNNs) or recurrent neural networks (RNNs), control the evolutions of AI technology.<sup>[5]</sup>

## 2. HISTORY OF AI

- Development of AI (1943-1952).
- The model of artificial neurones was first proposed in 1949 by Warren McCulloch and Walter Pitts in 1943.
- Donald Hebb updates a rule for modifying the connection strength between neurones in the year 1949. His rule is called learning.
- Alan Turing, who was an English mathematician, gave birth to machine learning in 1950. Alan Turing publishes "Computing Machinery and Intelligence", in which he performed a test which is used to check a machine's ability to indicate intelligence corresponding to human intelligence. This test is called the Turing Test.<sup>[6]</sup>
- In the year 1955, Allen Newell and Herbert A. Simon built the first artificial intelligence program, which was named "Logic Theorist". In this programme they had proved 38 to 52 mathematics theorems and found new and better-designed proofs for some theorems.
- In 1956 the word 'AI' was first approved by American computer scientist John McCarthy at Dartmouth.

- For the first time, AI was invented as an academic field. The golden years – early enthusiasm (1956-1974)
- In the year 1966, Joseph was the first researcher who emphasised developing algorithms which can solve various mathematical problems. This algorithm was named ELIZA.
- WABOT-1 was the first intelligent humanoid robot, which was built in Japan in the year 1972. The first AI winter (1974-1980).<sup>[7]</sup>
- The first AI winter lasted between the years 1974 and 1980. AI winter refers to the time period where computer scientists have a severe shortage of funding from the government for AI research. During the AI winter, an interest in publicity decreased. A boom of AI (1980-1987)
- Year 1980 – After the AI winter duration, AI came back with “Expert System”. Expert System was programmed to emulate the decision-making ability of a human expert.
- In the year 1980, the first national conference of the American Association of AI was held at Stanford University.
- IBM Deep Blue was the first computer to beat the world chess champion Gary Kasparov in 1997.<sup>[8]</sup>
- In the form of a Roomba, a vacuum cleaner AI entered the home for the first time in 2002.
- AI became advanced enough to come into the business industry up to the year 2006 and was used in huge business companies such as Facebook, Twitter, and Netflix, and also used AI deep learning with big data and artificial general intelligence.
- The year 2011, when a quiz show happened where it had to solve a complex question as well as riddles, and it had proved that it could understand natural languages and solve tricky questions too.
- The interval between the years 1987 and 1993 was another AI winter interval. Again, stockholders and government are stationary in capital for AI exploration due to high custody but not efficient results. The expert organisation, such as XCON, was very cost- effective.<sup>[9]</sup>

### 3. NEED OF AI IN PHARMACY PRACTICE

The combined role of artificial intelligence in pharmacy is reshaping pharmacy by fast-tracking drug discovery, improving clinical trials, and refining medication management and personalised patient care. Its request diagonally, the drug lifecycle boosts effectiveness and decision-making, though challenges linked to data security, ethics, and workforce readiness endure to limit extensive approval.<sup>[10]</sup>

Despite mounting interest, AI use in pharmacy is mainly limited to operative effectiveness, with negligible direct impact on patient consequences. Its comprehensive application is desirable to enhance medication safety, screening services, and observance while overpowering practice and research barriers to expand pharmacist-led patient care.<sup>[11]</sup>

Sympathetic pharmacists' knowledge and anxieties about AI are key to its safe and actual integration into practice. Problems like job security, ethics, and regulation must be spoken about with professional bodies if clear guidelines are to be established. Association across healthcare teams can ensure AI boosts patient care while maintaining safety and effectiveness through consideration of variances transversely across age and gender.<sup>[12]</sup>

AI can improve ICU pharmacology through modified dosing and projecting insights. Addressing data, authentication, and supervisory challenges is crucial. Cohesive as a helpful tool, AI accompanies clinicians and pharmacologists, refining executive and patient care.<sup>[13]</sup>

The combination of artificial intelligence in pharmacy practice is crucial for enhancing effectiveness and patient care.

Attentive training programmes and methodological provision are needed to equip pharmacists with the assistance and organisation required for effective AI use. Furthermore, institutional and financial incentives can inspire wider acceptance of AI technologies. These procedures communally support improved service distribution and better healthcare results in civic pharmacy situations.<sup>[14]</sup>

The increasing density of medication therapy highlights the need for artificial intelligence in pharmacy practice to advance patient safety and therapeutic outcomes. AI-based systems can assist in the early recognition of adverse drug trials, reduction of prescription mistakes, and prediction of patient-specific drug comebacks. Moreover, AI cares about personalised treatment planning, highlighting the need for further authentication through multicentre clinical training and cost-effectiveness examinations before extensive employment.<sup>[15]</sup>

AI is essential in pharmacy to improve effectiveness, make critical clinical decisions, and enhance patient safety. Clear, decent morals and supervisory measures are needed to protect data and ensure fair access. Research, training, and association are key to maximising AI's benefits while preserving core healthcare morals.<sup>[16]</sup>

Healthcare is moving to AI-driven solutions to improve compliance and effectiveness. In pharmacy, AI supports isolated discussions, telepharmacy, and smarter medication management, meeting the anxieties of modern, virtual care.<sup>[17]</sup>

AI is set to transform pharmacy by improving safety, effectiveness, and decision-making across the medication-use process. Pharmacists are critical in guiding its development, employment, and clinical submission. Actual incorporation requires education and training to equip professionals to harness AI's profits, ensuring patient care is enhanced while shaping the upcoming of pharmacy practice.<sup>[18]</sup>

Studies approximate that nearly 122 deaths per 100,000 population in India each year are attributable to deprived quality of healthcare, a rate higher than that reported in Brazil (74), Russia (91), China (46), South Africa (93), and adjacent countries including Pakistan (119), Nepal (93), Bangladesh (57), and Sri Lanka (51). India records roughly 2.4 million deaths per annum from curable situations, the highest among 136 countries studied. The sign extra specifies that death due to inferior care overrides losses caused by lack of access to healthcare. In 2022, an estimated 1.6 million Indians died as a result of poor care quality, nearly double the number who did not operate health services. Media reports, including *The Times of India*, have highlighted poor treatment as a major contributor to the country's overall mortality problem; that's why we need AI to diminish the mortality rate.<sup>[19]</sup>

#### 4. RISING OF AI IN WORLD HEALTHCARE

Nearly developed nations such as the United States and Japan are progressively improving regulatory backgrounds to speak to the developing trials of adaptive AI technologies. Disparate stationary procedures, these systems continue to learn and alter performance after arrangement, offering opportunities to develop healthcare delivery while confusing traditional regulatory error. In response, the US Food and Drug Administration has anticipated a total product life cycle background that stresses continuous valuation across development and post-market phases. Central to this method is regulatory examination of manufacturers' adherence to good machine learning practices, including robust data gaining, model training, tuning, testing, and transparency. This evolving regulatory model reproduces a broader global shift and permits wider international valuation.<sup>[20]</sup>

Artificial intelligence is renovating drug discovery for abandoned diseases, notably by using machine learning to identify talented malaria treatments. Malaria remains a major public health challenge in sub-Saharan Africa, triggering hundreds of thousands of deaths every year.<sup>[21]</sup>

Artificial intelligence has the potential to improve diagnostic truth, satisfy executives, and lead pharmacy-led patient management, predominantly in resource-constrained healthcare systems of developing countries with high patient burdens. However, its practical adoption remains limited due to inadequate regulatory standards, high execution and conservation costs, low digital literacy, and insufficient organisation and connectivity, which cooperatively restrict the full combination of AI into pharmacy and health care preparation.<sup>[22]</sup>

Modified medicine is based on the combination of genetic, environmental, and lifestyle data, producing extremely complex datasets that carry out advanced artificial intelligence-based analytical procedures. In low- and middle-income countries, nonstop development in AI technologies is vital to adapt these data into cost-effective, ascendable, and usually manageable precision healthcare strategies.<sup>[23]</sup>




Fig: 1.

In rising countries, the gap between AI-based forecasts and real-world biological results is predominantly pronounced. Although AI models can forecast likely contacts of mixtures under precise regenerations, they often fail to justify complex human physiology, limited clinical data, and population-specific distinctions. For example, a predicted high-affinity compound may not validate the same effectiveness in patients due to differences in metabolism, bioavailability, and interactions with local co-administered medications or traditional medicines.<sup>[24]</sup>

## 5. SIGNIFICANCE OF AI IN PHARMACY




Fig 2.

AI has the potential to play a significant role in Continuing pharmacy education (CPE), both in the design of educational activities and in how beginners cooperate with qualified progress prospects. Within the expansion of CPE goings-on, AI suggests possible profits such as enhancing instructional design and generating educational content. At the same time, concerns remain about fulfilled validity, ethical use, transparency, and the absence of consistent agendas.<sup>[25]</sup>

Artificial intelligence (AI) and systems-level education can recognise initial disease signs and develop the intervention gap. AI technology grows the intervention gap during disease expansion. As people isolate themselves from optimum health on the way to identified disease, they grow through subtle system worries, visible molecular variations, functional tissue variations, and early disease illness. AI-enabled uncovering identifies systems-based biomarkers and multitopic forms at earlier phases, while old-style detection depends on clinical symptoms and single biomarkers that seem significantly well along. This earlier uncovering meaningfully advances the intervention space, succeeding previous intervention with fine consequences and reduced prices.<sup>[26]</sup>

Artificial intelligence (AI) is transforming pharmaceutical sciences by converting drug discovery, development, and clinical requests. This chapter discovers the origins, moralities, and tenders of AI in pharmaceutical sciences, highlighting its role in overcoming ancient trials such as long-lasting timelines, high costs, and low success rates. AI technologies, as well as machine learning (ML) and deep learning (DL), enable data-driven insights, predictive modelling, and automation across the drug development duct. Key applications contain goal credentials, lead optimisation, ADMET profiling, clinical trial design, and modified medicine. The chapter also highlights the combination of AI with robotics for high-throughput research and the use of reproductive models for de novo drug design.<sup>[27]</sup>

AI can contribute to reducing development costs by enhancing research and development progress. Machine learning algorithms assist in investigational design and can forecast the pharmacokinetics and toxicity of drug applicants. This

ability enables the arranging and optimisation of lead compounds, reducing the need for wide-ranging and expensive animal testing. The request of AI to the study design helps with optimisation as well as deposits for the work related to the creation of the patient-centric type of design. AI uses methods for the gathering of the massive amounts of data generated from those clinical trials, thus reducing the amount of data workforce essential for the same.<sup>[28]</sup>

AI-driven styles in drug investigation and progress offer the potential to update and advance the credentials, optimisation, and design of novel beneficial applications, eventually leading to more well-organised and effective medications.<sup>[29]</sup>

## 6. MACHINE LEARNING IN THE PHARMACEUTICAL INDUSTRY

Machine learning plays a crucial role in forecasting and refining medication loyalty. By evaluating patient data, collected with prescription history, refill patterns, and socioeconomic issues, machine learning algorithms can diagnose persons at hazard of non-adherence (Osterberg & Blaschke, 2005). This analytical skill enables pharmacists to mediate proactively, offering made-to-order support, notices, or educational materials to enhance adherence and finally improve patient health results. Machine learning models can go outside traditional adherence predictors by joining diverse data sources, such as wearable device data or patient.<sup>[30]</sup>

One of the matters in the fields of health is concluding the disease of the patient. This issue can be determined through the machine learning estimate algorithms. In Chen, Hao, Hwang, Wang, & Wang (2017), the authors said that the machine learning procedures can be used to expect the patient's disease precisely. Every so often it also happens that the medicines are not offered in the pharmacy for the patients. This can be done by exercising the prototypical with the preceding year's data set, and then the model will predict the request of the future. If there is an unintentional shortage, then more medicines can be arranged. Machine learning algorithms can also be used for the one-to-one care. The AI and machine learning also minimise the chance of errors in storing the data. It can also help in providing the patient's data to the pharmacist so that the right medicine can be given to the patients.<sup>[31]</sup>

AI/ML has also been progressively cohesive in numerous sides of pharmacy exercise. AI/ML is operated in clinical decision support systems to guess adverse drug reactions, classify prescription errors, and provide dosage approvals, enhancing chronic disease treatment. Robotic technologies prepared with AI/ML can resourcefully update patient consultations, address patient investigations, manage drug records, and dispense medications. Still, AI platforms participating in health data and telemedicine can categorise at-risk patients and support pharmacists in transporting targeted interventions.<sup>[32]</sup>

Machine learning (ML) has suggestively advanced pharmaceutical trials in community pharmacies, hospital pharmacies, and pharmaceutical industry locations. Numerous notable healthcare organisations, such as Johns Hopkins University, Cleveland Clinic, and Mayo Clinic, have established computable advancements in the use of artificial intelligence in healthcare delivery. Community pharmacies have seen a 40% rise in drug adherence and a 55% drop in missed prescription refills since applying artificial intelligence (AI) technologies.<sup>[33]</sup>

Machine learning also reorganises drug delivery by improving amount chain administration and inventory control, reducing disorganisation, and certifying timely delivery. Analytical models can anticipate request instabilities, enhancing logistics to stop deficiencies or overstocking. These skills provide pharmacies with real-time market

perceptions, enabling faster revision to changing market trends and patient requirements. Furthermore, AI-enabled tools support tracking and measuring movement performance, helping continuous alteration for better results. Despite the several advantages, the application of AI in pharmacy marketing raises challenges, mainly around data privacy and ethical thoughts in patient-targeted presentation.<sup>[34]</sup>

ML algorithms are planned to handle high-dimensional datasets. Hence, resulting features from the current data are often involved, such as log-transformed data, products, and ratios of structures, or more progressive groupings. Such data transformation is a central preprocessing step that can have a thoughtful effect on the classical performance. Therefore, it is always a good impression to use available area knowledge and skill to come up with appropriate features, a process sometimes referred to as feature engineering. Data quality plays a key role in machine learning.<sup>[35]</sup>

Machine learning algorithms achieve calculations and learn from evidence to gain learning to perform predictions. Health informatics considers the actual use of probabilistic data for important leadership (9). Operating machine learning in the health informatics field has the best opportunities to improve the value, efficacy, and productivity of treatment and care. Good frameworks worldwide are stood up to with huge evidence in high dimensions, where the thought of a human is unbelievable, and automatic machine learning illustrations enormous outcomes.<sup>[36]</sup>

Since predictive analytics can be used in predicting many results, they can give pharmacy- informatics experts superior knowledge of the risks for specific prescription-related issues that all patients countenance.<sup>[37]</sup>

The incorporation of ML into multi-target drug discovery has unlocked new opportunities for considerate and optimising compound therapeutic policies, but it has also announced momentous challenges in data illustration, model generalisability, and clinical pertinence. Classical ML models, such as support vector machines (SVMs), random forests (RFs), and logistic erosion, have extended confirmed value in tasks like predicting DTI, aggressive effects, and pharmacokinetic profiles.<sup>[38]</sup>

The complex and nonlinear nature of multi-target drug discovery involves computational methods that can competently model exchanges across miscellaneous chemical and biological spaces. ML has turned out to be a powerful method to address these encounters, offering the litness to integrate heterogeneous data, learn unseen patterns, and make predictions at measure.<sup>[39]</sup>

Conventional ML algorithms have laid the foundation for multi-target drug discovery by subscription-mountable and understandable tools for prediction. SVMs and RFs are extensively implemented due to their strong performance in high-dimensional settings and strength against overfitting. These copies have been used for both dual arrangement and reversion responsibilities in DTI prediction. Other models such as k-nearest neighbours (k-NN) and naive Bayes (NB) classifiers offer effortlessness and rapidity, although they may lack the capacity to model complex affairs.<sup>[40]</sup>

The appearance of machine learning (ML) opened inclusive new prospects in several industries, such as biotechnology in medicine as well as drug discovery (Husnain et al., 2023). ML algorithms materialise to be a constant master that can successfully screen through vast and complex datasets and thus spot patterns and do advance results of these outcomes to support in the identification of drugs with beneficial effects.<sup>[41]</sup>

**Table 1: Commonly used machine learning models in pharmaceutical industries.**

| <b>AI/Machine Learning Models</b>              | <b>Description/Usage</b>                                                                                                                                                                                                                                                                                                                                                | <b>References</b> |
|------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| <b>Generative Adversarial Networks (GANs)</b>  | GANs are commonly used in drug merchandise development to produce novel chemical structures and enhance their belongings. GANs consist of a generator network that makes new fragments and a discriminator system that approximations their value, foremost to the group of organizationally various and functionally optimized drug claimants.                         | [42]              |
| <b>Recurrent Neural Networks (RNNs)</b>        | RNNs are habitually salaried for sequence-based farm obligations in drug advancement, such as prognostication protein structures, analysing genomic data, and designing peptide preparations. They capture chronological dependence and can harvest new categorizations constructed on scholarly enterprises.                                                           | [43]              |
| <b>Convolutional Neural Networks (CNNs)</b>    | CNNs are authentic in image-based responsibilities, as well as analysing molecular constructions and sleuthing probable drug areas. They can quotation appropriate constructions from molecular descriptions and aid in drug enterprise and aim authorizations                                                                                                          | [44]              |
| <b>Long Short-Term Memory Networks (LSTMs)</b> | LSTMs are a type of RNN that polish in exhibiting and expectant chronological dependencies. They have been castoff in pharmacokinetics and pharmacodynamics trainings to predict drug concentration-time outlines and guesstimate drug efficiency.                                                                                                                      | [45]              |
| <b>Transformer Models</b>                      | Modernizer models, such as the common BERT (Bidirectional Encoder Representations from Transformers), have been vigorous in expected verbal dispensation tasks in the pharmaceutical area. They can citation useful data from the scientific nonfiction, patent records, and clinical trial data, enabling researchers to make up-to-date inferences in drug expansion. | [46]              |
| <b>Reinforcement Learning (RL)</b>             | RL organizations have been convenient to progress drug dosing plans and progress improved handling plans. RL procedures acquire from associates with the situation to make liberal decisions, supporting in dose optimization, and enlightening patient assumptions.                                                                                                    | [47]              |
| <b>Bayesian Models</b>                         | Bayesian representations, such as Bayesian systems and Gaussian methods, are occupied for disinclination quantification and administrative in drug progress. They meet the requirements academics to make probabilistic guesstimates, assess menaces, and heighten investigational plans.                                                                               | [48,49]           |
| <b>Deep Q-Networks (DQNs)</b>                  | DQNs, a mixture of deep learning and underpinning learning, have been castoff to progress drug discovery developments by expectant the undertaking of complexes and portentous high-potential interviewees for more investigation.                                                                                                                                      | [50,51]           |
| <b>Autoencoders</b>                            | Autoencoders are unendorsed learning representations used for dimensionality drop and entrance extraction in drug development. They can confiscation vital appearances of fragments and involvement in multifarious transmission and virtual broadcast.                                                                                                                 | [52,53]           |
| <b>Graph Neural Networks (GNNs)</b>            | GNNs are considered to expansion graph-structured data, making them right for drug discovery farm duties that involve molecular structures. They can prototypical molecular charts, envision possessions, and relief in virtual broadcast and de novo drug design.                                                                                                      | [54,55]           |

## 7. DEEP LEARNING IN THE PHARMACEUTICAL INDUSTRY

DL supports the pharmaceutical business progress of new medicines and drug development. The skill looks into the patient's medical background and makes approvals based on that data. DL models are being used by researchers to improve mental health experimental practice. Neural networks that are deep are being used in research that seeks to better understand the impact of mental sickness and other illnesses on the nervous system.<sup>[56]</sup>

Deep learning methods have not been widely evaluated for a broad range of medical problems that could profit from their abilities. There are many aspects of deep learning that could be supportive in health care, such as its bigger concert, end-to-end learning scheme with cohesive feature learning, capability of handling complex and multi-modality information and so on.<sup>[57]</sup> Deep learning is used to learn the progression of disease, develop a personalised treatment plan and for overall patient supervision.<sup>[58]</sup>

### 7.1 Novel drug designing or de novo drug designing using deep learning

The progress of deep learning (DL) offers new occasions for the design and discovery of advanced drugs. In recent years, numerous DL-based de novo drug design algorithms have been established, and the successful application of DL in drug discovery was selected by Massachusetts Institute of Technology (MIT) Technology Review as one of the top 10 breakthrough knowledges in 2020.<sup>[59]</sup>

In addition, DL has been working for the growth of analysis approaches in data-driven fields such as biomedicine and healthcare.<sup>[60]</sup> The progress of DL-based de novo drug strategy approaches is still at an initial stage; experimental proof of its usefulness in drug discovery is crucial for the continuous development of these methods and to support their extensive uptake into medicinal chemistry preparation and drug guidelines.<sup>[61]</sup>

The chief advantages of DL refer to the scale and the complexity of the neural networks used to build robust and analytical models, as well as the elasticity in their architecture, allowing for revisions to specific difficulties.<sup>[62]</sup>

## 8. COMPUTER VISION

Computer Vision (CV) is one of the expanding modern AI technologies. The spreading and supervision of medications are about to change by using CV for medication organisation. This system scans pharmaceutical makers and has a track of the process from delivery to track using cameras, sensors, and computer algorithms.<sup>[63]</sup>

The research of computer vision, imaging meting out and pattern recognition has made considerable progress through the previous several years. Also, medical imaging has involved increasing reflection in current eternities due to its energetic fundamental in healthcare submissions.<sup>[64]</sup>

Computer vision (CV), a category of artificial intelligence (AI) that conducts digital videos or an arrangement of pictures to identify content, has been used broadly across industries in recent centuries. But, in the healthcare industry, its claims are limited by factors like privacy, safety, and ethical concerns. Despite this, CV has the potential to improve patient monitoring and system efficiencies while reducing workload.<sup>[65]</sup>

The field of healthcare is in a state of continual development, determined by the combination of novel digital skills. Computer vision (CV) and artificial intelligence (AI) are developing as key players in renovating patient attention. Moreover, AI and CV aid in pre-operative arrangement, providing surgeons with a full roadmap of the technique, fulfilling the need for investigative surgery, and facilitating quicker recovery times for patients. Participating AI and CV in healthcare systems also enables real-time patient data and proactive involvements.<sup>[66]</sup> Computer vision is changing healthcare, especially in medical imaging and primary diagnosis, but faces challenges such as inadequate annotated datasets, generalisation matters, data privacy, and the difficulty of medical pictures. Future guidelines include improving model transparency, progressing privacy-conserving methods like federated learning, and encouraging equitable requests.<sup>[67]</sup>

The deep learning approach in computer vision for medical imaging is the top secret to aiding physicians in exploiting the precision of diagnoses; it is harmless and safe to use for assisting doctors in medical imaging analysis.<sup>[68]</sup>

**Table 2: Specialized AI Software/tools Used Across the Pharmaceutical Industry.**

| Software/ Platform                          | Key Capability                                                                         | Primary Users                      | Reference |
|---------------------------------------------|----------------------------------------------------------------------------------------|------------------------------------|-----------|
| <b>Pharma.AI (Insilico Medicine)</b>        | End-to-end mark credentials and de novomolecule peer group using propagative AI copies | Sanofi, multiple industry partners | [69]      |
| <b>AlphaFold (Isomorphic Labs/DeepMind)</b> | High-accuracy estimate of 3D protein assemblies permitting structure-based drug design | Eli Lilly, Novartis                | [70]      |
| <b>Prezent (Astrid AI)</b>                  | AI-assisted age group of technical and regulatory-compliant performances               | Global pharmaceutical companies    | [71]      |
| <b>YEZA.ai</b>                              | Computerized adversative occasion consumption and dealing out for pharmacovigilance    | Emerging pharma and biotech firms  | [72]      |
| <b>Dheera</b>                               | AI-driven agreement hazard prophecy and worth system supervision                       | Indian pharmaceutical industry     | [73]      |

## 9. ADVANTAGES OF AI IN PHARMACY AND HEALTHCARE



**Fig - 3.**

### 9.1 Accelerated Drug Discovery and Design

AI procedures can be used to warn gigantic chemical public libraries to presume how feasible drug entrants will narrate with biological areas. This diminishes the retro and worth of the R&D categorisation by recognising "hits" and "leads" much sooner than obsolete research laboratory assemblies.<sup>[74]</sup>

### 9.2 Implementation of Personalised Medicine

AI investigates a patient's unique genetic profile, lifestyle, and medical history to mention modified therapeutic routines. This verifies that handlings are custom-made to precise organic profiles, growing value by up to 30% in nearly all cases.<sup>[75]</sup>

### 9.3 Optimised Medication Adherence

AI-powered virtual supporters and smart monitoring systems track patient medication designs. These systems send real-time reminders and provide 24/7 support, suggestively reducing the "burden of forgetfulness" in chronic disease administration.<sup>[76]</sup>

#### 9.4 Automated Pharmaceutical Inventory Management

In presentation and infirmary pharmacies, AI supposes future medication requirements created on ancient data and epidemiologic tendencies. This moderates waste from the dead routine and stops drug scarcities.<sup>[77]</sup>

#### 9.5 Enhanced Clinical Trial Efficiency

AI restructures clinical trials by labelling appropriate candidates concluded Electronic Health Records (EHRs) and intensive care contestants in real-time via vestures. This declines dropout rates and grows the assortment of trial models.<sup>[78]</sup>

#### 9.6 Reduction in Medication Errors

AI-grounded clinical decision support systems (CDSS) act as a "safety net" for pharmacists by flagging feasible drug-drug connections, improper dosages, or antipathy risks before a prescription is allotted.

#### 9.7 Streamlined Administrative Workflows

By using Natural Language Processing (NLP) and Robotic Process Automation (RPA), healthcare employees can schematise monotonous tasks like billing, prior approvals, and informing patient records, permitting more time for unswerving patient consideration.<sup>[79]</sup>

#### 9.8 Strengthens Pharmacovigilance

AI significantly recovers pharmacovigilance by automating the discovery of adverse drug reactions, enhancing signal identification, and permitting proactive safety replies quicker than traditional physical methods.<sup>[80]</sup>

#### 9.9 Early Outbreak and Epidemic Forecasting

AI studies global health data to detect patterns that advise the start of a wide-ranging. These analytical models agree healthcare systems should assign resources and develop vaccines or treatments proactively.<sup>[81]</sup>

### 10. CHALLENGES AND LIMITATIONS OF AI IN PHARMACEUTICALS




Fig- 4.

### 10.1 The "Black Box" Nature of AI

Deep learning representations are commonly "black boxes", signifying their policymaking technique is not transparent to human clinicians. This scarcity of explainable AI (XAI) makes it hard for pharmacists to trust or demonstrate why a certain drug or dosage was recommended.<sup>[82]</sup>

### 10.2 Data Privacy and Security Risks

AI involves vast quantities of slight patient health information (PHI). This forms crucial vulnerabilities for data cracks, unauthorised access, and cyberattacks, typically when data is common between organisations or stored in the cloud.<sup>[83]</sup>

### 10.3 High Implementation and Maintenance Costs

Participating AI in existing healthcare set-up needs immense sincere investment in hardware, secure databases, and specific employees. This economic barrier often removes smaller pharmacies and hospitals from approving these skills.<sup>[84]</sup>

### 10.4 Lack of Human Connection and Empathy

AI lacks the demonstrative intelligence and compassion vital for patient-centred care. There is a hazard that over-automation may moderate the critical human affiliation between a pharmacist/clinician and their patient.<sup>[85]</sup>

### 10.5 Algorithmic Bias and Limited Generalisability

AI models skilled on non-representative datasets may produce unfair outcomes, leading to imprecise medication references for certain populations and growing health biases.<sup>[86]</sup>

## CONCLUSION

The combination of artificial intelligence denotes a model shift in pharmaceutical sciences and healthcare, stirring the industry from outdated, inefficient procedures on the way to a data-driven, "intelligent" future. AI's capability to modernise directorial workflows, predict epidemics, and initialise therapeutic schedules offers a commanding solution to worldwide health challenges, with high death rates related to poor care superiority.

Though, the "expanding" of AI is not without important friction. The technical complication of deep learning models generates a transparency gap (the "black box" problem) that can delay clinical hope. Furthermore, ethical worries regarding data security and the potential for algorithmic bias demand a proactive, universal method of regulation and uniform "good machine learning practices".

Finally, the effective approval of AI in pharmacy rests on a cooperative collaboration between technology and human skill. Rather than swapping the pharmacist, AI should be viewed as a sophisticated "safety net" that authorises clinicians to focus more on direct, vicarious patient care while the technology holders the load of compound data processing. Moving forward, targeted education and institutional provision will be energetic to preparing the upcoming generation of healthcare authorities with the skills compulsory to attach AI's full possible without harm and impartially.

## REFERENCES

1. K.-K. Mak and M. R. Pichika, "Artificial intelligence in drug development: present status and future prospects," *Drug discovery today*, 2019; 24(3): 773–780.
2. S. Das, R. Dey, and A. K. Nayak, "Artificial intelligence in pharmacy," *Indian J Pharm Educ Res*, 2021; 55(2): 304–318.
3. S. Dashpute *et al.*, "Artificial intelligence and machine learning in the pharmaceutical industry," *International Journal of Pharmacy and Pharmaceutical Research (IJPPR)*, 2023; 28(2): 111–131.
4. S. A. Damiani, "Digital pharmaceutical sciences," *AAPS PharmSciTech*, 2020; 21(6): 206.
5. M. K. Dr. Rama Brahma Reddy D , A. Sai Gagan, S.Gopi chand, U. Guna teja, "AN OVERVIEW ON ARTIFICIAL INTELLIGENCE IN PHARMACY," *IJNRD2506298*, 2025; 10(6): p. 8.
6. W. Duch, R. Setiono, and J. M. Zurada, "Computational intelligence methods for rule- based data understanding," *Proceedings of the IEEE*, 2004; 92(5): 771–805.
7. F. Jiang *et al.*, "Artificial intelligence in healthcare: past, present and future," *Stroke and vascular neurology*, 2017; vol. 2, no. 4.
8. J. V. Gobburu and E. P. Chen, "Artificial neural networks as a novel approach to integrated pharmacokinetic—pharmacodynamic analysis," *Journal of pharmaceutical sciences*, 1996; 85(5): 505–510.
9. J. Dasta, "Application of artificial intelligence to pharmacy and medicine," *Hospital pharmacy*, 1992; 27(4): 312–5, 319.
10. H. Allam, "Prescribing the future: The role of artificial intelligence in pharmacy," *Information*, 2025; 16(2): 131.
11. H. Jessica, R. Britney, E.-D. Sarira, A. Parisa, and Z. Joe, "Applications of artificial intelligence in current pharmacy practice: A scoping review," *Research in Social and Administrative Pharmacy*, 2025; 21(3): 134–141.
12. K. A. Gustafson *et al.*, "Pharmacists' perceptions of artificial intelligence: A national survey," *Journal of the American Pharmacists Association*, 2025; 65(1): 102306.
13. M. Gijssen and J. J. De Waele, "Does artificial intelligence close gaps in clinical pharmacology in the ICU?," *Intensive Care Medicine*, 2025; 51(2): 385–388.
14. A. S. Jarab *et al.*, "Artificial intelligence in pharmacy practice: attitude and willingness of the community pharmacists and the barriers for its implementation," *Saudi Pharmaceutical Journal*, 2023; 31(8): 101700.
15. S. S. Alqahtani, S. J. Menachery, A. Alshahrani, B. Albalkhi, D. Alshayban, and M. Z. Iqbal, "Artificial intelligence in clinical pharmacy—A systematic review of current scenario and future perspectives," *Digitalhealth*, vol.11, p.20552076251388145, 2025.
16. H. E. Hasan, D. Jaber, O. F. Khabour, and K. H. Alzoubi, "Ethical considerations and concerns in the implementation of AI in pharmacy practice: a cross-sectional study," *BMC Medical Ethics*, 2024; 25(1): 55.
17. M. Stasevych and V. Zvarych, "Innovative robotic technologies and artificial intelligence in pharmacy and medicine: paving the way for the future of health care— a review," *Big data and cognitive computing*, 2023; 7(3): p. 147.
18. N. Schutz *et al.*, "ASHP statement on the use of artificial intelligence in pharmacy," *American Journal of Health-System Pharmacy*, 2020; 77(23): 2015–2018.
19. M. N. Akhtar, A. Haleem, and M. Javaid, "Intelligent Pharmacy".
20. J. Morley, L. Murphy, A. Mishra, I. Joshi, and K. Karpathakis, "Governing data and artificial intelligence for health

- care: developing an international understanding," *JMIR formative research*, 2022; 6(1): e31623.
21. H. J. Oladipo *et al.*, "Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers," *Annals of Medicine and Surgery*, 2022; 81: p. 104366.
  22. V. Zuhair *et al.*, "Exploring the Impact of Artificial Intelligence on Global Health and Enhancing Healthcare in Developing Nations," *Journal of Primary Care & Community Health*, 2024; 15: p. 21501319241245847. doi: 10.1177/21501319241245847.
  23. J. Guo and B. Li, "The application of medical artificial intelligence technology in rural areas of developing countries," *Health equity*, 2018; 2(1): 174–181.
  24. A. Wang *et al.*, "Development and application of artificial intelligence in traditional Chinese medicine research and development," *Chinese Medicine*, 2026; 21(1): 17.
  25. L. T. Murry, K. Catledge, M. Holderly, D. V. Travlos, and J. P. Engle, "Exploring AI integration in continuing pharmacy education: A survey of emerging institutional practice and initial guidance," *Currents in Pharmacy Teaching and Learning*, 2026; 18(3): 102538.
  26. N. Rappaport, B. Nogal, K. Perrott, V. Domina, L. Hood, and N. D. Price, "Early detection of wellness-to-disease transitions in the AI era: Implications for pharmacology and toxicology," *Annual Review of Pharmacology and Toxicology*, 2026; vol. 66.
  27. K. Shaikh, R. Thanki, and A. Shaikh, "Introduction to Artificial Intelligence in Pharmaceutical Sciences," in *Artificial Intelligence in Drug Discovery and Development*: Springer, 2026; pp. 1–23.
  28. L. K. Vora, A. D. Gholap, K. Jetha, R. R. S. Thakur, H. K. Solanki, and V. P. Chavda, "Artificial intelligence in pharmaceutical technology and drug delivery design," *Pharmaceutics*, 2023; 15(7): 1916.
  29. V. P. Chavda, K. Anand, and V. Apostolopoulos, *Bioinformatics tools for pharmaceutical drug product development*. John Wiley & Sons, 2023.
  30. E. P. Adeghe, C. A. Okolo, and O. T. Ojeyinka, "A review of the use of machine learning in predictive analytics for patient health outcomes in pharmacy practice," *OARJ of Life Sciences*, 2024; 7(1): 052–058.
  31. P. K. Donepudi, "AI and machine learning in retail pharmacy: Systematic review of related literature," *ABC journal of advanced research*, 2018; 7(2): 109–112.
  32. X. Zhang, C. C. S. Tsang, D. D. Ford, and J. Wang, "Student pharmacists' perceptions of artificial intelligence and machine learning in pharmacy practice and pharmacy education," *American Journal of Pharmaceutical Education*, 2024; 88(12): 101309.
  33. M. D. Simpson and H. S. Qasim, "Clinical and Operational Applications of Artificial Intelligence and Machine Learning in Pharmacy: A Narrative Review of Real-World Applications," *Pharmacy*, 2025; 13(2): 41.
  34. G. K. RINJI, O. M. AKACHUKWU, A. U. PRECIOUS, A. A. LUQMAN, and G. O. EIGBOKHAN, "Digital transformation in pharmacy marketing: integrating AI and machine learning for optimized drug promotion and distribution," *WORLD*, 2022; 15(2): 749–762.
  35. S. Badillo *et al.*, "An introduction to machine learning," *Clinical pharmacology & therapeutics*, 2020; 107(4): 871–885.
  36. A. Holzinger, "Machine learning for health informatics," in *Machine Learning for Health Informatics: State-of-the-Art and Future Challenges*: Springer, 2016, pp. 1–24.
  37. N. Alhorishi, M. Almeziny, and R. Alshammari, "Using machine learning to predict early preparation of pharmacy prescriptions at psmmc-a comparison of four machine learning algorithms," *Acta Informatica Medica*, 2021; 29(1):

p.21.

38. D. R. Serrano *et al.*, "Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine," *Pharmaceutics*, 2024; 16(10): 1328.
39. A. U. Rehman *et al.*, "Role of artificial intelligence in revolutionizing drug discovery," *Fundamental Research*, 2025; 5(3): 1273–1287.
40. X. Bi, Y. Wang, J. Wang, and C. Liu, "Machine learning for multi-target drug discovery: challenges and opportunities in systems pharmacology," *Pharmaceutics*, 2025; 17(9): 1186.
41. F. M. Alshabrm, F. F. A. Alkhayl, and A. Rehman, "Novel drug discovery: Advancing Alzheimer's therapy through machine learning and network pharmacology," *European Journal of Pharmacology*, 2024; 976: p. 176661.
42. T. Sousa, J. Correia, V. Pereira, and M. Rocha, "Generative deep learning for targeted compound design," *Journal of chemical information and modeling*, 2021; 61(11): 5343–5361,
43. R. Rajalingham, A. Piccato, and M. Jazayeri, "Recurrent neural networks with explicit representation of dynamic latent variables can mimic behavioral patterns in a physical inference task," *Nature Communications*, 2022; 13(1): 5865.
44. S. Nag *et al.*, "Deep learning tools for advancing drug discovery and development," *3 Biotech*, 2022; 12(5): 110.
45. X. Liu *et al.*, "Long short-term memory recurrent neural network for pharmacokinetic- pharmacodynamic modeling," *International journal of clinical pharmacology and therapeutics*, 2021; 59(2): 138.
46. A. Turchin, S. Masharsky, and M. Zitnik, "Comparison of BERT implementations for natural language processing of narrative medical documents," *Informatics in Medicine Unlocked*, 2023; 36: p. 101139.
47. L. Huo and Y. Tang, "Multi-objective deep reinforcement learning for personalized dose optimization based on multi-indicator experience replay," *Applied Sciences*, 2022; 13(1): 325.
48. A. Olivier, M. D. Shields, and L. Graham-Brady, "Bayesian neural networks for uncertainty quantification in data-driven materials modeling," *Computer methods in applied mechanics and engineering*, 2021; 386: p.114079.
49. M. Magris and A. Iosifidis, "Bayesian learning for neural networks: an algorithmic survey," *Artificial Intelligence Review*, 2023; 56(10): 11773–11823.
50. T.-H. Pham, Y. Qiu, J. Zeng, L. Xie, and P. Zhang, "A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing," *Nature machine intelligence*, 2021; 3(3): 247– 257.
51. J. Meyers, B. Fabian, and N. Brown, "De novo molecular design and generative models," *Drug discovery today*, 2021; 26(11): 2707–2715.
52. A. Khadela, S. Popat, J. Ajabiya, D. Valu, S. Savale, and V. P. Chavda, "AI, ML and other bioinformatics tools for preclinical and clinical development of drug products," *Bioinformatics tools for pharmaceutical drug productdevelopment*, 2023; pp.255–284.
53. N.-M. Koutroumpa, K. D. Papavasileiou, A. G. Papadiamantis, G. Melagraki, and A. Afantitis, "A systematic review of deep learning methodologies used in the drug discovery process with emphasis on in vivo validation," *International Journal of Molecular Sciences*, 2023; 24(7): 6573.
54. M. Tang, B. Li, and H. Chen, "Application of message passing neural networks for molecular property prediction," *Current Opinion in Structural Biology*, 2023; 81: 102616.
55. P. Reiser *et al.*, "Graph neural networks for materials science and chemistry," *Communications Materials*, 2022; 3(1): 93.

56. A. Rahman *et al.*, "Machine learning and deep learning-based approach in smart healthcare: Recent advances, applications, challenges and opportunities," *AIMS Public Health*, 2024; 11(1): p. 58.
57. R. Miotto, F. Wang, S. Wang, X. Jiang, and J. T. Dudley, "Deep learning for healthcare: review, opportunities and challenges," *Briefings in bioinformatics*, 2018; 19(6): 1236–1246.
58. D. Kaul, H. Raju, and B. Tripathy, "Deep learning in healthcare," in *Deep learning in data analytics: Recent techniques, practices and applications*: Springer, 2021; pp. 97–115.
59. M. Wang *et al.*, "Deep learning approaches for de novo drug design: An overview," *Current opinion in structuralbiology*, 2022; 72: pp.135–144.
60. P. Mamoshina, A. Vieira, E. Putin, and A. Zhavoronkov, "Applications of deep learning in biomedicine," *Molecular pharmaceutics*, 2016; 13(5): 1445–1454.
61. V. D. Mouchlis *et al.*, "Advances in de novo drug design: from conventional to machine learning methods," *International journal of molecular sciences*, 2021; 22(4): p. 1676.
62. C. F. Lipinski, V. G. Maltarollo, P. R. Oliveira, A. B. Da Silva, and K. M. Honorio, "Advances and perspectives in applying deep learning for drug design and discovery," *Frontiers in Robotics and AI*, 2019; 6: p. 108. [Online]. Available:<https://www.frontiersin.org/journals/robotics-and-ai/articles/10.3389/frobt.2019.00108/full>.
63. M. Javaid, A. Haleem, R. P. Singh, and M. Ahmed, "Computer vision to enhance healthcare domain: An overview of features, implementation, and opportunities," *Intelligent Pharmacy*, 2024; 2(6): 792–803.
64. J. Gao, Y. Yang, P. Lin, and D. S. Park, "Computer vision in healthcare applications," *Journal of healthcare engineering*, 2018; vol.2018: p.5157020.
65. H. Lindroth *et al.*, "Applied artificial intelligence in healthcare: a review of computer vision technology application in hospital settings," *Journal of Imaging*, 2024; 10(4): p. 81.
66. W. Shafik, A. F. Hidayatullah, K. Kalinaki, and M. M. Aslam, "Artificial intelligence (AI)-assisted computer vision (CV) in healthcare systems," in *Computer vision and AI- integrated IoT technologies in the medical ecosystem*: CRC Press, 2024, pp. 17–36.
67. G. AlZohbi, "Challenges and Future Directions in Computer Vision for Healthcare," in *Computer Vision in Healthcare*: CRC Press, 2026; pp. 20–35.
68. C. Angelica, H. Purnama, and F. Purnomo, "Impact of computer vision with deep learning approach in medical imaging diagnosis," in *2021 1st international conference on computer science and artificial intelligence (ICCSAI)*, 2021; vol.1:IEEE,pp.37–41
69. Y. A. Ivanenkov *et al.*, "Chemistry42: An AI-based platform for de novo molecular design," *arXiv preprint arXiv: 2101.09050*, 2021.
70. F. Ren *et al.*, "AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor," *Chemical science*, 2023; 14(6): 1443–1452.
71. E. J. Topol, "High-performance medicine: the convergence of human and artificial intelligence," *Nature medicine*, 2019; 25(1): 44–56.
72. A. Bate and S. F. Hobbiger, "Artificial intelligence, real-world automation and the safety of medicines," *Drugsafety*, 2021; 44(2): 125–132,
73. Z. Zhu, "Intelligent information management enables quality-by-design in pharmaceutical production," *ScientificReports*, 2025; 15(1): 44201.
74. T. Nazari, E. Ezzati, H. R. Rasekh, and Z. Gharib-Naseri, "Application of artificial intelligence in the

- pharmaceutical industry," *Health Technology Assessment in Action*, 2023.
75. Y. A. Fahim, I. W. Hasani, S. Kabba, and W. M. Ragab, "Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives," *European Journal of Medical Research*, 2025; 30(1): p.848.
76. G. Anandharaj *et al.*, "A Review on Applications of Artificial Intelligence in Clinical Pharmacy," *Journal of Pharma Insights and Research*, 2025; 3(4): 001–014.
77. H. Hamishehkar and M. Shahidi, "Impact of Artificial Intelligence on the Future of Clinical Pharmacy and Hospital Settings," *Journal of Research in Pharmacy Practice*, 2025; 14(3): 87–97.
78. A. Blanco-Gonzalez *et al.*, "The role of AI in drug discovery: challenges, opportunities, and strategies," *Pharmaceuticals*, 2023; 16(6): p. 891.
79. R. Awasthi *et al.*, "Artificial Intelligence in Healthcare: 2024 Year in Review," *medRxiv*, 2025; p. 2025.02.26.25322978.
80. R. C. Algarvio, J. Conceição, P. P. Rodrigues, I. Ribeiro, and R. Ferreira-da-Silva, "Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool," *International Journal of Clinical Pharmacy*, 2025; 47(4): pp. 932–944.
81. S. K. Bhattamisra, P. Banerjee, P. Gupta, J. Mayuren, S. Patra, and M. Candasamy, "Artificial intelligence in pharmaceutical and healthcare research," *Big Data and Cognitive Computing*, 2023; 7(1): p. 10,
82. V. Grover and M. Dogra, "Challenges and Limitations of Explainable AI in Healthcare," in *Analyzing Explainable AI in Healthcare and the Pharmaceutical Industry*: IGI Global Scientific Publishing, 2024; pp. 72–85.
83. V. Nizam and A. Aslekar, "Challenges of applying AI in healthcare in India," *Journal of Pharmaceutical Research International*, 2021; vol. 33, no. 36B, pp. 203–209.
84. M. I. A. Fahim, T. S. Tonny, and A. Al Noman, "Realizing the potential of AI in pharmacy practice: Barriers and pathways to adoption," *Intelligent Pharmacy*, 2024; 2(3): 308–311.
85. E. Mehraeen *et al.*, "Artificial intelligence challenges in the healthcare industry: a systematic review of recent evidence," *Healthcare Technology Letters*, 2025; 12(1): p. e70017.
86. A. Rajkomar, M. Hardt, M. D. Howell, G. Corrado, and M. H. Chin, "Ensuring fairness in machine learning to advance health equity," *Annals of internal medicine*, 2018; 169(12): 866–872.